Company profile: Neuron23
1.1 - Company Overview
Company description
- Provider of drug development programs for neurological and inflammatory diseases, including Parkinson's and Alzheimer's. Pipeline includes NEU-723, a brain-penetrant LRRK2 inhibitor in Phase 1 for Parkinson's; NEU-411, a follow-on LRRK2 inhibitor for Parkinson's expected to enter clinical trials in 2023; and TYK2 programs targeting systemic inflammation, neuroinflammation and MS.
Products and services
- Central TYK2: A therapeutic-program targeting neuroinflammation and multiple sclerosis (MS), centralizing TYK2 efforts on MS and neuroinflammation
- NEU-411: A follow-on, brain-penetrant LRRK2 inhibitor for Parkinson's disease, expected to enter clinical trials in 2023 to further target LRRK2 within the brain
- NEU-723: A brain-penetrant LRRK2 inhibitor in Phase 1 clinical trials for Parkinson's disease, engineered to inhibit LRRK2 activity in the brain.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neuron23
MDDX
HQ: United States
Website
- Description: Provider of technologies and affordable research applications that unlock insights your data did not reveal, improving efficiency and scalability of multicenter trials; offering nearly a dozen tools used by thousands of researchers in dozens of global research trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDDX company profile →
Synthesis Med Chem
HQ: United States
Website
- Description: Provider of small molecule drug discovery services, offering integrated drug discovery from hit identification to preclinical candidate nomination; medicinal and synthetic chemistry; custom synthesis; targeted protein degradation (PROTACs & molecular glues); antibody-drug conjugate development; and hit discovery supported by protein production and structural biology services from Viva Biotech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synthesis Med Chem company profile →
Kallik
HQ: United Kingdom
Website
- Description: Provider of labeling content management and artwork generation solutions for regulated markets including pharmaceutical, medical devices, cosmetics, and chemicals. Offers Veraciti, a cloud-based system for end-to-end labeling and artwork management with automated artwork generation, asset and phrase management, AI-enabled onboarding and migration, and 24/7 global customer support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kallik company profile →
Tx3
HQ: United States
Website
- Description: Provider of automated quality and compliance SaaS solutions for software testing within Life Science companies, enabling agile adoption and efficient adherence to regulatory requirements such as 21 CFR Part 11. Offerings include Tricentis Tosca, qTest, NeoLoad, LiveCompare, and Data Integrity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tx3 company profile →
Trials.ai
HQ: United States
Website
- Description: Provider of an AI-powered Smart Protocol system that optimizes clinical trial protocols and guides research teams in designing trials for speed and success, helping pharma, biotech, and device companies get treatments to patients faster.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trials.ai company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neuron23
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neuron23
2.2 - Growth funds investing in similar companies to Neuron23
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neuron23
4.2 - Public trading comparable groups for Neuron23
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →